1-7 of 7
Zena Komrokji
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CMML Is in the Eye of the Be_Who_ Lder: Interrogating the Newly Proposed Entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, David Sallman, Eric Padron
Journal: Blood
Blood (2024) 144 (Supplement 1): 1004.
https://doi.org/10.1182/blood-2024-205451
Published: 2024
Journal Articles

High-Risk Ccus Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms

Zhuoer Xie, Zena Komrokji, Michael Otterstatter, Ling Zhang, Lynn C. Moscinski, Najla H. Al Ali, David Sallman, Jeffrey E Lancet, Amy E. DeZern, Mikkael A. Sekeres, Rami S. Komrokji, Nancy Gillis, Eric Padron
Journal: Blood
Blood (2024) 144 (Supplement 1): 354.
https://doi.org/10.1182/blood-2024-203837
Published: 2024
Journal Articles

IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD)

Rami S. Komrokji, Najla H. Al Ali, Zhuoer Xie, Zena Komrokji, Joseph E. Jabbour, Onyee Chan, Seongseok Yun, Andrew T. Kuykendall, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman
Journal: Blood
Blood (2024) 144 (Supplement 1): 3228.
https://doi.org/10.1182/blood-2024-204167
Published: 2024
Journal Articles

Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Fadi G. Haddad, Hagop M. Kantarjian, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Jeffrey L. Jorgensen, Joseph E. Jabbour, Sa A. Wang, Yesid Alvarado Valero, Xuemei Wang, Alessandra Ferrajoli, Diane Habib, Jan A. Burger, Courtney D. DiNardo, Zena Komrokji, Lucia Masarova, Tapan M. Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Rebecca Garris, Elias Jabbour
Journal: Blood
Blood (2024) 144 (Supplement 1): 4194.
https://doi.org/10.1182/blood-2024-210642
Published: 2024
Journal Articles

Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Marker in Myelodysplastic Syndromes

Rami S. Komrokji, Zena Komrokji, Najla H. Al Ali, Zhuoer Xie, Onyee Chan, Andrew T. Kuykendall, Joseph E. Jabbour, Alison R. Walker, Jeffrey E Lancet, Eric Padron, David Sallman
Journal: Blood
Blood (2024) 144 (Supplement 1): 3217.
https://doi.org/10.1182/blood-2024-205861
Published: 2024
Journal Articles

Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL

Diane Habib, Hagop M. Kantarjian, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Jayastu Senapati, Kelly S. Chien, Guillermo Garcia-Manero, Zena Komrokji, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, Rebecca Garris, Farhad Ravandi, Elias Jabbour
Journal: Blood
Blood (2024) 144 (Supplement 1): 2811.
https://doi.org/10.1182/blood-2024-210501
Published: 2024
Journal Articles

Outcomes of Adult Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL) Having Myeloid Type Mutations Treated with Inotuzumab/Blinatumomab Containing Frontline Regimens

Jayastu Senapati, Hagop M. Kantarjian, Clark Robinson, Koichi Takahashi, Nitin Jain, Fadi G. Haddad, Courtney D. DiNardo, Sanam Loghavi, Guilin Tang, Guillermo Montalban-Bravo, Tapan M. Kadia, Naval Daver, Koji Sasaki, Zena Komrokji, Rebecca Garris, Guillermo Garcia-Manero, Farhad Ravandi, Nicholas J. Short, Elias Jabbour
Journal: Blood
Blood (2024) 144 (Supplement 1): 1461.
https://doi.org/10.1182/blood-2024-204181
Published: 2024